#Global Hemophilia Therapeutics Market World Hemophilia Therapeutics Market Europe Hemophilia Therapeutics Market Uk Hemophilia Therapeutics | Explore Tumblr posts and blogs

bearni · 3 years ago

Text

Global Hemophilia Therapeutics Market By Type (hemophilia A,hemophilia B,hemophilia C), By Application (HospitalsClinicsAmbulatorySurgicalCenters), By Country, and Manufacture - Industry Segment, Competition Scenario and Forecast by 2029

Industry analysis and future outlook on Hemophilia Therapeutics Global Market brings a systematic perspective of the market execution and assists in strategic decision making for worldwide and additionally the regional situation. Detailed sections provides in-depth arrangement, the Hemophilia Therapeutics contemplate that make sense of different perspectives relating to the global market. To begin with, the Hemophilia Therapeutics market definition, applications, arrangement, and industry esteem chain structure are incorporated into the answer, to target gathering of people on restricting Hemophilia Therapeutics market elements including drivers, limitations, openings, patterns, applications, topographical/local Hemophilia Therapeutics markets, and aggressive scene.

Global Hemophilia Therapeutics Industry Market was valued at USD XX Million in the year 2020. The market is further estimated to grow at a CAGR of XX% from 2020 to reach USD XX Million by the year 2029.

Get Quick Free Sample Brochure report at: https://www.globalresearchview.com/report/global-hemophilia-therapeutics-market-by/GRV52959/request-sample/

Hemophilia Therapeutics market rivalry by top makers/players, with Hemophilia Therapeutics deals volume, Value (USD/Unit), Revenue (Mn/Bn USD) and market size for every producer/player; the significant players include:

Bayer AG Pfizer Inc. Novo Nordisk A/S Baxter International Inc. Biogen Idec Inc. Genetics Institute Alpha Therapeutics Corporation Expression Therapeutics Swedish Orphan Biovitrum AB.

Worldwide Hemophilia Therapeutics statistical surveying report uncovers that the Hemophilia Therapeutics business will develop with pivotal CAGR over the estimated forecast period of 2021 and 2029. The global Hemophilia Therapeutics market in forecast years 2021-2029, is expected to hit Mn/Bn$ XX USD by 2029. The Hemophilia Therapeutics market gives broad development openings over the both created and creating economies. Further, the Hemophilia Therapeutics business sectors could profit without a doubt from the expanding interest to bring down Hemophilia Therapeutics expenses of treatment over the globe.

Inquiry for Buying report to get customization at: https://www.globalresearchview.com/report/global-hemophilia-therapeutics-market-by/GRV52959/inquiry

Key Highlights of the Report:

Hemophilia Therapeutics Market Report provides forecast and industry outlook for the period of 2021-2029 with 2020 as the base year and covering historic data for years 2015-2019.

Hemophilia Therapeutics Market outlook with Porter’s 5 Forces Analysis will provide market dynamics (Drivers, Restraints, Opportunities & Threats).

Hemophilia Therapeutics Competitive landscape section gives you the competitive edge over other key players in the market (Key Business Strategies, Recent Development M&A, Company Overview, Products/Services Portfolio & Financial Overview).

Hemophilia Therapeutics Technological Scenarios & Expected Developments.

Hemophilia Therapeutics End-Use Industry & Consumer Behaviour Trends.

Hemophilia Therapeutics Export-Import Scenario.

Hemophilia Therapeutics Regulatory Policies across each region.

Hemophilia Therapeutics In-depth analysis on Industry Trends & Dynamics across each segment covered in the report.

Based on Type, Hemophilia Therapeutics market report shows development rate of each type, covers:

hemophilia A hemophilia B hemophilia C

End clients/applications, Hemophilia Therapeutics market report centers around the status and viewpoint for best applications/end clients, development rate for every application, this can be isolated into:

Hospitals Clinics AmbulatorySurgicalCenters

Access More Information at: https://www.globalresearchview.com/report/global-hemophilia-therapeutics-market-by/GRV52959

In conclusion, the global Hemophilia Therapeutics industry report unveils research finding, outcomes, conclusions. Likewise, disclose various Hemophilia Therapeutics data sources, traders/vendors, suppliers, manufacturers, sales channel, and addendum. In short, the overall Hemophilia Therapeutics report is a lucrative document for people implicated in Hemophilia Therapeutics market.

Global Impact of COVID-19 Analysis:

COVID19 is an unrivaled global public health emergency that affects almost every industry, so the projected long-term impact will affect industry growth over the forecast period. The report provides insights into COVID19, taking into account changes in consumer behavior and demand, purchasing behavior, supply chain diversion, the dynamics of current market forces, and significant government intervention. Insights, analysis, estimates and forecasts considering the impact of COVID19 on the market.

About Us:

GlobalResearchView (GRV) is one of the leading market research company which aims to serve the most excellent research to the various sectors of business. We are prominent in satisfying all kinds of market research needs.

Jennifer Da (Head Global Business Development) – Global Research View(GRV) 701, Milton Avenue, East Ham,London. United kingdom. Pincode - 4E6 1BN Email: [email protected] Websites: www.globalresearchview.com Tel: +44 020 8638 7098

#Global Hemophilia Therapeutics Market World Hemophilia Therapeutics Market Europe Hemophilia Therapeutics Market Uk Hemophilia Therapeutics

0 notes

jackssresearch · 2 years ago

Text

MTPE Device Market Growth Analysis By 2029 | Innovation, Latest Trend and Business Opportunities | By Straits Research

mTPE Device Market Highlights:

mTPE Device Market Anticipated to Touch a CAGR of 7.6% During the Forecast Period 2017-2029

mTPE Device Market Growth Report provides in-depth information on the Market trends, size, share, growth factors, innovations, competitive landscape, business challenges, and more. The historical data in this report confirms the growing demand on a Global, national and regional scale.

The study of the Global industry covers everything from comprehensive research to Market forecasts, prospects, risks, and vendor knowledge. Research on mTPE Device helps to understand the industry prospects and growth opportunities. The report utilizes advanced tools such as SWOT analysis and Porter’s Five Forces analysis to accurately estimate Market and revenue growth. The report also provides an extensive analysis of the impact of the COVID-19 pandemic and how it has contributed to the progress of the Market.

Click the link to get a sample copy of the report: https://straitsresearch.com/report/mtpe-device-market/request-sample

Major Market Players:

Baxter International Inc

Market segmentation by Type and Application:

By Therapeutic Application Plasma or red cell exchange Cell depletion Granulocyte collection Stem cell collection By Therapeutic Type Hemophilia Bone marrow Platelet transfusion Renal dialysis By End-User Hospitals Research Laboratories Blood bank Blood transfusion laboratories

Regional Analysis:

Global mTPE Device Market Trends in key regions:

North America (US, Canada, Mexico)

Europe (Germany, UK, France, Italy, Spain, Russia, etc.)

Asia Pacific (China, Japan, South Korea, Australia, India, Southeast Asia, etc.)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, etc.)

South America (Brazil, Argentina, Colombia, Chile, etc.)

Each of these regions are analyzed based on Market research results across major countries in these regions for a macro-level understanding of the Market.

Impact on Industry Due to COVID-19

Since the outbreak of the COVID-19 virus in December 2019, the disease has spread to almost every country around the world as the World Health Organization (WHO) declared a public health emergency. The Global impact of Coronavirus Disease 2019 (COVID-19) is already starting to be felt and will have a major impact on the mTPE Device Market in 2020. The outbreak of COVID-19 has affected several aspects such as flight cancellations, travel bans, quarantines, restaurant closures, restrictions on all indoor/outdoor events, more than 40 countries declared a state of emergency, massive slowdowns in supply chains, stock Market volatility, Declining business confidence, growing fears of the population, and uncertainty about the future.

Market Factors Described in the Report:

Market Overview: Includes other chapters briefly describing the scope of the mTPE Device Market research, Market analysis by major players, Market analysis by segments, applications, types, and the study.

Summary: The mTPE Device Market share report evaluates key Market functions such as revenue, price, capacity, utilization, gross production, production, consumption, import and export, supply and demand, cost, Market share, CAGR, and gross margin. Additionally, the report offers a comprehensive study of key Market dynamics and latest trends, as well as relevant Market segments and sub-segments.

Regional Survey: All regions and countries analyzed in the mTPE Device Market report have been surveyed based on Market size by application, Market size by product, key players and Market forecasts.

Market Forecast: Here, the report offers a complete forecast of the Global mTPE Device Market size by product, application, and region. It also provides Global sales and revenue forecasts for all years of the forecast period.

The survey includes historical and forecast data that makes the report easy to access documentation, including industry executives, marketing, sales and product managers, consultants, analysts, and clearly presented tables for stakeholders looking to the core. Industry data. It will be a valuable resource and graph.

You can Buy This Report Here: https://straitsresearch.com/buy-now/mtpe-device-market/global/

The following questions answered in the mTPE Device Market report:

How has the COVID-19 pandemic impacted the Global mTPE Device Market Players?

What is the essential strategy available for the growth & development of the Global mTPE Device Market?

What are the key segments explained in the Global mTPE Device Market report?

What are the strategically phases determined for marking an entry of the players in the Global mTPE Device Market?

What are the major governing frameworks and technology trends involved in the mTPE Device Market?

Trending Report:

https://www.openpr.com/news/2490181/north-america-windshield-snow-brush-market-growth-report-2021

https://www.openpr.com/news/2522640/global-dementia-care-products-market-share-is-estimated-to-grow

https://www.openpr.com/news/2532815/global-colloids-blood-plasma-market-share-is-projeted-to-reach

About Us:

StraitsResearch.com is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us: Email: [email protected] Address: 825 3rd Avenue, New York, NY, USA, 10022 Tel: +1 6464807505, +44 203 318 2846 Website: https://straitsresearch.com/

#mTPE Device Market mTPE Device Market Share mTPE Device Market Size mTPE Device Market Research mTPE Device Industry What is mTPE Device?

0 notes

industryinsights · 3 years ago

Text

Renal Cancer Drug Market Analysis, Revenue Share, Company Profiles, Launches, & Forecast Till 2027

The renal cancer drug market is expected to witness tremendous growth owing to the rising prevalence of high blood pressure. Other key factors such as the change to sedentary lifestyle, increase in smoking, growing consumption of alcohol are contributing to the growth of the market. However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments and the side effects and reaction associated with treatments are expected to restrict the market growth during the forecast period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6466

Segmentation

The global renal cancer market is segmented on the basis of therapeutic class, pharmacologic class, type, and end-user. The renal cancer drug market, by therapeutic class, is categorized into targeted therapy and immunotherapy. On the basis of pharmacologic class, the market is segmented into angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies and cytokine immunotherapy (IL-2). On the basis of type, the market is segmented into clear cell, papillary, chromophobe, oncocytic, collecting duct and other. On the basis of end- user the market is segmented hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers and other.

Regional Analysis

The Americas is the largest in the market owing to the increasing prevalence of stroke and high blood pressure and growing healthcare expenditure. The American Cancer Society estimated about14,970 people in 2018, will die due to kidney cancer in the US. Thus, the growing cases of kidney cancer facilitate the market growth in this region.

Europe (UK, Belgium, France, and Netherlands) is the second largest renal cancer drug market during the forecast period. The increasing occurrence of renal cancer drives the market in this region. According to Cancer Research UK in 2015, there were 12547 new cases of kidney cancer in the UK. Thus, the growing cases of kidney cancer facilitate the market growth.

Asia-Pacific was projected to be the fastest growing region for the global renal cancer drug market in 2017. The market is expected to witness growth owing to the rising prevalence of smoking and alcohol consumption in this region. According to the World Health Organization in 2015, 47.6% of people smoked tobacco in countries like China and Japan, respectively. This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, the rising oncology and new cancer treating technology both at the hospital level and in the community are expected to influence the market in a positive way.

Key Players

Some of the key players in the global renal cancer drug market are Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/renal-cancer-drug-market-6466

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Body Sensors Market - https://icrowdnewswire.com/2021/01/21/body-sensors-market-share-is-projected-to-reach-usd-25-billion-at-a-10-cagr-by-2023/

Hemophilia Treatment Market - https://icrowdnewswire.com/2021/01/21/hemophilia-treatment-market-size-is-expected-to-exhibit-a-6-1-cagr-by-2023/

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

0 notes

alliedanalytics · 3 years ago

Text

Positive impact of covid-19 on Rare hematology disorders market

Rare hematology disorders market Outlook - 2027

Rare blood diseases include sickle cell disease, beta thalassemia, follicular lymphoma, multiple myeloma, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, and others. Blood develops from hematopoietic stem cells (HSC) and formation takes place in the bone marrow through a sequence of the regulated process known as hematopoiesis. Blood contains component such as plasma, RBS, WBC, and platelets. Blood disorders include bleeding disorders such as hemophilia, blood clots; blood cancers (leukemia, lymphoma, and myeloma). When the normal process of the blood development fails, abnormal blood cell type is produced, which causes blood cancer and other blood disorders. The rare hematological disease includes anemia-type red blood cell conditions, white blood cell dysfunctions, immuno-disorders and other platelet-based abnormalities. The other hemoglobinopathies are also on the rise due to increasing immigration of carriers from underdeveloped nations to developed regions of the world. The rare blood disorders are difficult to diagnose and treat.

The coronavirus COVID-19 has affected 213 countries and territories around the world. COVID-19 has created new challenges that are requiring manufacturers to innovate at speeds they never have before. Supply chain disruptions, social distancing on high-touch assembly lines, limited ability to travel, and the need for oversight add significant complexity to today’s processes. The outbreak of coronavirus disease 2019 (COVID-19) has created a global health crisis that has had a deep impact on the manufacturing market there is a shortage in supply of raw materials from Chinese manufacturers which has resulted in a severe demand-supply gap. The manufacturers are further expected to be stranded on raw material orders owing to the logistics industry being significantly impacted due to lockdown amid COVID-19. This has all affected the market adversely causing a slowdown in the rare hematology disorders market due to shortage of supply and manufacturing drugs.

Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/11306

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Drivers:

Increased prevalence:

Rare diseases comprise a growing public health priority, as they affect above 300 million people globally and they are difficult to diagnose and treat. There is a pressing need for better ways to detect and diagnose rare diseases, as well as to provide companion diagnostics for therapy guidance, clinical trials enrollment and therapy monitoring applications. In the U.S., the condition is considered as rare when it affects less than 200,000 people in the United States or prevalence of 5 per 10,000. In Europe, 5 in 10,000 citizens are considered as rare diseases. According to Eurordis (European organization of rare diseases), there are approximately 6000 to 8000 rare diseases. Around 15 million people across the globe suffer from thalassemic disorders and nearly 1.5% of the world population is estimated to be a carrier of β-thalassemia. Rare hematology disorder treatment among the geriatric population base will show boast in future. An overall occurrence of anemia ranges from 10% to 24% among the senior adults. As the age of patient increases, the need for hematology disorder care also increases. Thus, the growing population of geriatric age group will increase the chances of developing rare blood disorders among adults, thereby boosting the demand for hematology disorder treatment in the forecast period.

Development of new therapies:

Global Blood Therapeutics (GBT) is developing biologics for the treatment of sickle cell disease. The company lead candidate, voxelotor (GBT440) is in Phase 3 trials and being investigated for the treatment of sickle cell disease. The candidate is a hemoglobin S polymerization inhibitor and its mechanism of action is modulation hemoglobin affinity for oxygen. FDA has granted has breakthrough therapy, fast track, orphan drug and rare pediatric disease designations to Vozelotor. Imara is developing novel therapeutics for patients suffering from sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Its lead candidate is IMR-687, a small molecule inhibitor of phosphodiesterase-9 (PDE9i) for the treatment of sickle cell disease. Launched in April 2016 by orphan drug accelerator Cydan Development. Cyclerion is involved in developing therapies for treating sickle cell disease (SCD) and diabetic nephropathy. They are focused on the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Their lead candidate, Olinciguat, which is a vascular guanylate cyclase agonist. The candidate is in phase II clinical trial. They have granted Orphan Drug Designation for SCD by the U.S. Food and Drug Administration. The development of such therapies and treatment for the diseases will drive the Rare hematology disorders market growth.

Restrains:

High cost of treatment and late detection in developing countries will prove as the restrain for market growth.

Key benefits of the report:

This study presents the analytical depiction of the global rare hematology disorders industry along with the current trends and future estimations to determine the imminent investment pockets.

The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global rare hematology disorders market share.

The current market is quantitatively analyzed from 2020 to 2027 to highlight the global rare hematology disorders market growth scenario.

Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.

The report provides a detailed global rare hematology disorders market analysis based on competitive intensity and how the competition will take shape in coming years.

Read more: https://www.alliedmarketresearch.com/rare-hematology-disorders-market-A10941

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 [email protected] Web:https://www.alliedmarketresearch.com Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

#Rare hematology disorders market size #Rare hematology disorders market growth #Rare hematology disorders market trends

0 notes

latestanalysis · 4 years ago

Text

Europe Genetic Testing Market Top 5 Competitors, Regional Trend, Application, Marketing Strategy, Outlook Analysis and Forecast

Europe Genetic Testing market was valued at US$ 2,472.0 Mn in 2020 and it is projected to reach at US$ 4,262.4 Mn by 2027, at a CAGR of 8.5% during the forecast period. Major factors accounting for this growth include the increase in incidences of genetic, infectious & chronic diseases, reduction in prices of genetic sequencing, rising adoption of precision medicine diagnostic techniques. Genetic testing is defined as medical test which detect changes in proteins, genes or chromosomes. The test results are able to confirm a speculated underlying genetic condition or aid in determining an individual’s chance of developing/ passing on a genetic disorder.

Market Drivers: Increasing focus of government for genetic testing awareness

The growing focus by governments of several countries, to regulate& create awareness regarding genetic tests, has successfully resulted in the faster adoption of these tests worldwide. The rise in Research & Development funding, with the strong market presence by major players in the market, has created a strong entry barrier for new entrants. The increasing innovation in product design, improvement in quality, and strong distribution partnerships are key factors to retain a competitive edge in the market.

Get Sample Copy of this Report @ https://qualiketresearch.com/request-sample/Europe-Genetic-Testing-Market/request-sample

Rising demands for newborn and pre-natal screening to detect congenital abnormalities, growing application of bio banking services that involve DNA testing as a crucial step for cord blood banking are further attributive for progress in this sector. Growing Physicians’ interest towards genetic testing in order to determine patient’s health at various stages of disease development is another factor anticipated to fuel demand in the coming years.

Factors such as increasing implementation of personalized medicine applications to treat chronic disorders enhancing the need for HLA typing & DNA identification for therapy are expected to further add to the growing demand for DNA diagnostics. Moreover, hi-tech advancements which result into commercialization of next generation diagnostic & testing solutions making use of genetic analysis are anticipated to positively impact on Europe genetic testing market growth.

Market Restraints: COVID-19 has negative impact on Europe genetic testing market

The COVID-19 pandemic has left a prominent impact on the growth of the genetic testing market over the crisis. As per the research article published in Genetics in Medicine (2020), all the clinical genetic testing was restricted & telemedicine-based consultations and counseling were adopted across the globe. According to this study, 112 prenatal & 156 clinical genetics/cancer patients were evaluated in a span of one month at the Columbia University Irving Medical Center (CUIMC).

Most of the genetic testing services are adopted virtualization, coupled with home testing kit or home sample collection, to combat the transmission of the SARS-CoV2 virus. Moreover, as per the research article published in the Journal of Medical Genetics (2020), there was hindrance reported in accessing genetic testing blood draws, as a result of that the genetic testing was prominently impacted, wherein a reduction in genetic testing from 97.7% to 74.1% was observed during this period. Hence, COVID-19 is anticipated to have a direct & indirect impact on the genetic testing market over the ongoing crisis period.

Europe Genetic Testing Market Share Analysis by Technology

Based on Technology, the Europe genetic testing market is categorized intoCytogenetics Testing, Biochemical Testing and Molecular Testing.

Cytogenetic testing segment is the second highest revenue generating technology in Europe genetic testing market. The growth is attributed due to rise in healthcare expenditure that has resulted in the increasing use of cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies. Also, cytogenetic is used in the development of targeted cancer treatment, personal medicine, and others. Currently, a wide range of techniques such as comparative genomic hybridization, fluorescence, karyotyping, and others are employed for the screening of genetic abnormalities and cancers. These techniques employ the use of cytogenetic products including media, kits, reagents, and others. This factor is expected to drive the Cytogenetic testing segment over the forecast period.

Europe Genetic Testing Market Share Analysis by Type

Based on type segment, the Europe genetic testing market is categorized into Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive & Presymptomatic Testing, Prenatal Testing and Others.

Diagnostic Testing has accounted for the highest market share in 2020. This is due to rising incidence of genetic and other chronic disorders. As per the information published on World Health Organization (WHO), the increase in prevalence of inherited diseases like sickle cell anemia, cystic fibrosis and hemophilia will contribute the overall market size for genetic tests. Additionally, early disease diagnosis further allows patients to undergo therapeutic treatment at an early stage that minimizes the severity of disease leading to reduced mortality rate and hence proving beneficial for the segment expansion.

Europe Genetic Testing Market Share Analysis by Disease

Based on Disease segment, the Europe genetic testing market is categorized into Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease and Others.

Cancer disease has accounted for the highest market share in 2020. Genetic testing is very helpful to estimate the chances of developing cancer throughout an individual’s lifetime by examining for specific changes in chromosomes and genes, proteins. Cancer, globally, is the 2nd leading reason of death, and approximately70% of deaths from cancer occurs in low- and middle-income countries which raises the demand for genetic testing. As, significant enhancements can be made in the lives of cancer persons by diagnosing at an initial stage & avoiding postponements in care resulting in reduced morbidity, less expensive treatment & greater probability of surviving. This factor creases the demand for genetic testing for cancer.

Europe Genetic Testing Market Share Analysis by Country

Germany, The U.K., Italy and France are top country in Europe genetic testing market. These countries collectively accounted for more than 50% of market share in 2020. The presence of developed healthcare infrastructure, strong government initiatives and proactive funding for genetic testing research, and high prevalence of chronic diseases are the major drivers for industrial growth in these countries.

Other European countries is expected to create significant opportunity in genetic testing due to rising research incentives provided by the government in developing economies of this region that enable R&D and commercialization of technologically advanced products. Moreover, higher availability of target population owing to the incidence of chronic diseases in this region is also expected to supplement growth in the coming years.

Recent Developments:

In March 2020, Abbott had launched molecular point-of-care test to detect novel coronavirus in short time period, 5-15 minutes. The ID NOW platform is small, lightweight & portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and the scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing. The company has already shipped 150,000 PCR tests to its existing customers, for use on its m2000 Real-time in vitro diagnostic system.

In March 2021, Qiagen had unveiled its Cloud-based platform, QIAsphere, that helps laboratories & QIAstat-Dx users remotely monitor tests & instrument status around the clock. QIAstat-Dx connectivity with the platform will enable QIAGEN technical service to check customers instrument health in real time, simultaneously offering them a quick response to reduced systems downtime. QIAsphere connectivity is made possible by connecting a small connectivity hub, QIAsphere Base (Qbase), to QIAstat-Dx, as well as other platforms, in less time through LAN or Wi-Fi network of hospitals, retaining sensitive data of patients within the hospital network.

In December 2020, CENTOGENE and Alnylam Pharmaceuticals has launched a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”).

Market Segmentation

The Europe Genetic Testing Market is segmented into type such as Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive & Presymptomatic Testing, Prenatal Testing, and Others. On the basis of Disease, market is segmented into Alzheimer's Disease, Cancer , Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia , Huntington's Disease, and Others. Further, market is segmented into technology such as Cytogenetic Testing, Biochemical Testing, and Molecular Testing.

Also, the Europe Genetic Testing Market is segmented into various countries such as Germany, UK, France, Turkey, Switzerland, Norway, Sweden, Spain, Italy, Denmark, Finland, Iceland, Poland, Luxembourg, Netherlands, and Belgium.

Market Key Players

Various key players are listed in this report such as Abbott Laboratories, Illumina Inc., Eurofins Scientific, Qiagen, Elitech Group, Thermo Fischer Scientific, Centogene AG, Blueprint Genetics, 23andMe Inc., F. Hoffmann-La Roche Ltd, etc.

Market Taxonomy

By Type

Carrier Testing

Diagnostic Testing

Newborn Screening

Predictive & Presymptomatic Testing

Prenatal Testing

Others

By Disease

Alzheimer's Disease

Cancer

Cystic Fibrosis

Sickle Cell Anemia

Duchenne Muscular Dystrophy

Thalassemia

Huntington's Disease

Others

By Technology

Cytogenetic Testing

Biochemical Testing

Molecular Testing

By Country

Germany

France

Turkey

Switzerland

Norway

Sweden

Spain

Italy

Denmark

Finland

Iceland

Poland

Luxembourg

Netherlands

Belgium

Browse Full Research Report @ https://qualiketresearch.com/reports-details/Europe-Genetic-Testing-Market

About Us

QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition.

#Europe Genetic Testing Market size #Europe Genetic Testing Market Share #Europe Genetic Testing Market Trend #Europe Genetic Testing Mark

0 notes

mrunalnerkarblog · 4 years ago

Text

Worldwide Industry for Plasma Fractionation to 2027 - by Product, Application, End-user and Region

Plasma fractionation is a process of separating various components of plasma, which in turn is a component of blood obtained through blood fractionation. Plasma is separated and can be used for many different medical applications. Plasma is taken from donors when whole blood is donated, or by plasmapheresis - a process by which the liquid part of the blood, or plasma, is separated from the blood cells and plasma is retained. This plasma can be used as Fresh Frozen Plasma (FFP) for replacement of clotting factors. Most plasma is used for products which derived from plasma fractionation. Plasma comprehends thousands of diverse proteins, but only about 20 of these are used to produce therapeutic plasma products. These fit into three classes’ immunoglobulins, clotting factors, and albumin.

Growth of this market is mainly attributed to increasing incidence of bleeding and immune disorders, growing geriatric population, and growing use of immunoglobulin and alpha-1-antitrypsin. Plasma fractionation is used for treating protein deficiency in healthcare applications and also as a packaging material for industrial applications. The prime function of plasma fractionation is removal or inactivation of viruses and prions.

Request for Sample copy: https://www.coherentmarketinsights.com/insight/request-sample/529

According to Centers of Disease Control (CDC) statistic, in 2012 chronic diseases were one of the major causes of death and disability in the U.S., with an estimated 117 million people suffering from some form of chronic disease. Developed diagnostic facilities, and comfort of access to healthcare along with increasing incidence and prevalence of chronic diseases all over the world, are some factors responsible for the rising demand for plasma derived products and is expected to drive the plasma fractionation market during the forecast period. The increase in geriatric population all over world is an important factor for plasma fractionation market, mainly due to the risk of complications of hemophilia, such as intracranial hemorrhage, inhibitor development, and joint diseases, increases along with the age of a person.

Key Developments:

In September 2019, Biopharma, a Ukraine based company which is specialized for the production of plasma-based, recombinant and other drugs, launched a new plant for plasma fractionation in Bila Tserkva, Ukraine. The company offers a unique plasma fractionation technology which allows the plasma components of the blood to be processed for the extraction of life-saving drugs and the company is equipped with GMP – certified equipments and facilities. The launch of the company has put Ukraine almost on the same page as that of USA, Austria, and Germany. In the facility, production of blood products like Albumin, Bioven and Immunoglobulin is expected to help treat diseases caused due to immunodeficiency.

In June 2019, Egypt initiated a project for the setup of the blood plasma fractionations and processing plant in the country in order to establish labs for the plasmapheresis.

Plasma Fractionation Market Taxonomy

By Product Type

Albumin

Immunoglobulins

Coagulation Factor Concentrates

By Application

Neurology

Hematology

Immunology

Critical Care

By End User

Hospitals

Clinical Research Laboratories

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

To Get Istant Access purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/529

Key players operating in the global plasma fractionation market are CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated, Octapharma AG, and Kedrion S.p.A held the major share of the plasma fractionation market and will continue to take over the market. Other major players are Bio Products Laboratory, Sanquin, China Biologic Products, Inc., Biotest AG, and Laboratoire Français du Fractionnement et des Biotechnologies.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: [email protected]

#Plasma Fractionation Market Plasma Fractionation Market Analysis Plasma Fractionation Market Growth Plasma Fractionation Market Size

0 notes

speedylightheart · 4 years ago

Text

Global Gene Editing Service Market Analysis, Size, Share, Growth, Trends and Forecast 2020-2025

Gene Editing Service Market is valued at USD 3.53 Billion in 2018 and expected to reach USD 9.55 Billion by 2025 with a CAGR of 15.3% over the forecast period.

Gene Editing Service Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025. Increasing prevalence of cancer disease and technological advancement in gene editing sector driving the gene editing service market.

Scope of Gene Editing Service Market-

Gene Editing Service also referred as the genome editing. Gene editing is a group of technologies that enables gene professionals to change an organism's DNA. These technologies enable genetic material to be added, altered or removed at particular location in the gene. There are multiple approaches involve in genome editing, among them well know is CRISPR-Cas9, this is stand for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The CRISPR-Cas9 system has multiple advantages and generated a lot of excitement in the scientific community owing to it’s cheaper, faster, accurate, and more efficient than any other existing genome editing methods.

Gene editing is one of the great interests in the prevention and treatment of human diseases including to understand diseases using animal and cells models, to determine predicted approach is safe and effective for use in human. Gene editing also being explored in research on a wide range of diseases, including single-gene disorders like hemophilia, cystic fibrosis and sicle cell diseases among others. It is capable to treatment and prevention of more critical disease including cancer, mental illness, heart disease, and human immunodeficiency virus (HIV) infection. In February 2020, significant milestone added in the gene editing, a US trial safely showed CRISPR gene editing on 3 cancer patients.

Gene editing service market report is segmented based on technology, delivery method, application, end users, services and by regional & country level. Based upon technology, gene editing service market is classified into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN and others. Based upon delivery method, gene editing service market is classified into Ex-Vivo and In-Vivo. Based upon application, gene editing service market is classified into cell line engineering, animal genetic engineering, plant genetic engineering and other applications. Based upon end users, gene editing service market is classified into biotechnology & pharmaceutical companies, academic & government research institutes and contract research organizations. Based upon service, gene editing service market is classified into contract and in-house.

Get Sample Copy of This Premium Report: @ https://brandessenceresearch.com/requestSample/PostId/1322

The regions covered in this gene editing service market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of gene editing service is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Gene Editing Service Companies

Gene editing service market report covers prominent players like Merck, Horizon Discovery Limited, Lonza, GenScript, Eurofins Scientific, Thermo Fisher Scientific, Sangamo Therapeutics, Editas Medicine, CRISPR Therapeutics, Precision Biosciences, Oxford Genetics , Synthego, Vigene Biosciences, EpiGenie, Integrated DNA Technologies, New England Biolabs, OriGene Technologies, Intellia Therapeutics, Transposagen Biopharmaceuticals, Creative Biogene, Agilent Technologies, Danaher, ToolGen, Cellecta, Genecopoeia, and Calyxtand among others.

Gene Editing Service Market Dynamics –

Advancement in current gene editing technologies including TALEN, ZFN, CRISPR, antisense, and other technologies are driving the growth of gene editing service market. Increasing pipeline products in the companies is also expected fuelling the growth over the forecast period. Moreover, utilization of this techniques by using various approaches including correction in the deleterious mutations, disruption of viral DNA is expected to boost adoption. In addition, increasing collaboration of pharmaceutical companies with universities owning to increase of drastic interest in gene editing in the last few years are the factors driving the growth of market.

On the other flip, owning to off-target toxicity effects of nucleases is still a safety concern for the market. In addition to this, the IP disputes pertaining to CRISPR technology amongst the industry players is expected to negative impact on growth of market in near future. Nevertheless, CRISPR is expected to be the most significant cancer treatment gene editing technology since the CRISPR technique is affordable, easy to use and works with high throughput experiments, this can create the huge opportunity in the market and expected to drive the growth of market over the forecast period.

Gene Editing Service Market Regional Analysis –

North America is dominating the gene editing service market followed by Europe due to the rising awareness about the growing prevalence of gene-related disorder. For instance, as per the National Cancer Institute (NCI), in 2016, around 1 million cancer cases were diagnosed in the in the U.S.A. Moreover, increased healthcare infrastructure and spend on health in the region fueling the growth of market, for instance, as per the data of American Health Care, in the year of 2017, the United States spent around USD 3.5 trillion, or 18 percent of total GDP, on health expenditures.

Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to positive trends associated with rising number of biopharmaceutical establishments and biotechnology companies, growing investments made by companies and government in gene editing service research. For instance, Japan has a large number of companies those are involved in synthetic biology and gene editing service. Furthermore, Rapid technological development in China and India is expected to attract global players for investments to develop gene editing service technology in the Asia Pacific region will also bolster the market growth over the forecast period.

Key Benefits for Gene Editing Service Market Reports –

Global Market report covers in depth historical and forecast analysis.

Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Market report helps to identify opportunities in market place.

Global Market report covers extensive analysis of emerging trends and competitive landscape.

Gene Editing Service Market Segmentation –

By Technology: (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Others

By Delivery Method: Ex-Vivo, In-Vivo

By Application: Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Other Applications

By End-use: Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations

By Service: Contract, In-house

Regional & Country Analysis North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa.

Get Full Report :@ https://brandessenceresearch.com/healthcare/gene-editing-service-market-industry-analysis

About Us:

Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

0 notes

strategyr-blog · 6 years ago

Text

Rising Demand for Blood Components and Need for Blood Transfusion in Therapy to Drive Growth in the Global Apheresis Equipment Market

The global Apheresis Equipment market is projected to reach US$3.6 billion by 2024, driven by the increasing prevalence of blood disorders and chronic diseases requiring blood transfusion.

Apheresis refers to a procedure where blood from a person (patient or donor) is passed through a medical device in order to extract the required components, such as red blood cells, platelets, plasma and others. Apart from its use in separating specific blood components from donor blood, the apheresis process is also utilized for the treatment of specific diseases conditions such as leukemia. Global market for apheresis equipment continues to witness stable growth driven by the rising adoption of therapeutic and donor apheresis. The increasing prevalence of blood disorders such as sickle cell anemia, blood cancer, and hemophilia and the rising need for various blood products is driving the demand for apheresis equipment, globally. Specifically, the increasing incidence of various illnesses in the elderly and the subsequent rise in demand for blood and blood components is expected to foster market growth.

Growing awareness about platelet donation in developed economies and the subsequent growth in the number of platelet donors and increasing R&D investments of biopharmaceutical companies also contribute to apheresis market growth. Also driving growth is the increase in causality figures that is leading to enhanced need for surgical procedures that require blood transfusion. Rising awareness about apheresis blood collection and escalating demand for automated blood component separation procedures also favor growth in the apheresis equipment market. Technology advances such as automated interface system, continuous flow centrifugation and features such as screen navigation, GUI display, and custom anticoagulant infusion system are also expected to foster growth in the apheresis equipment market.

As stated by the new market research report on Apheresis Equipment, the United States represents the largest regional market, worldwide. Growth in the US apheresis equipment market is driven by the rising incidence of hematological disorders and other chronic conditions such as neurological disorders and increasing demand for technologically advanced and automated products. Further, access to advanced healthcare services and favorable reimbursement framework also favors market growth. Asia-Pacific is forecast to grow at the fastest CAGR of 12.1% over the analysis period. The promising outlook for Asia-Pacific is attributed to the rising prevalence of blood-related disorders in emerging economies of China and India. Increase in surgical procedures and trauma and accident cases and improving healthcare infrastructure also bode well for the market.

Major players in the market include Asahi Kasei Medical Co., Ltd., B Braun Melsungen AG, Cerus Corporation, Fresenius Kabi AG, Haemonetics Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., Mallinckrodt Pharmaceuticals, Medica SpA, NIKKISO Europe GmbH, and Terumo BCT Inc., among others.

The research report titled “Apheresis Equipment – Market Analysis, Trends, and Forecasts” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific (Australia, China and Rest of Asia-Pacific) and Rest of World. The market is analyzed by the product segments - Equipment for Therapeutic Apheresis and Equipment for Donor Apheresis. Global market for Apheresis Equipment is additionally analyzed by Procedure – Photopheresis, Plasmapheresis and Others. Further, the US market is analyzed by the Therapeutic Area – Neurology, Hematology & Oncology, Rheumatology, and Others (Includes GvHD, Solid Organ Transplant Rejection, Inflammatory Bowel Disease, Mastocytosis, Pemphigus Vulgaris, and Hepatitis C).

For enquiries e-mail us at [email protected] or [email protected].

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn

#Apheresis Equipment #Donor Apheresis Equipment #Therapeutic Apheresis Equipment #Fresenius Kabi AG #Haemonetics Corporation

0 notes

pandeprabhakar01-blog · 6 years ago

Text

Biopharmaceuticals Market Comprehensive Analysis and Future Estimations 2023

A biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.

Key Strategies of leading players

Enhance productivity and optimizing back end manufacturing processes

Product enhancement through integrating new strategies involving big data, advanced analytics into traditional manufacturing processes

Growing businesses through serving into new application areas and identifying pockets of growth in emerging markets

Focusing on cost effective production of devices with stability and robustness

Strategies for Product differentiation and adjusting to the life cycle changes

Strengthening collaboration with suppliers and distributors

More focused strategies are found in the report

Get Sample of Report at https://www.researchformarkets.com/sample/global-biopharmaceuticals-market-113093

This report focuses on the Biopharmaceuticals in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

It is costly to discover and develop new drugs/medicines due to expensive research processes, Costs associated with clinical trials, resource-intensive approval procedures and costs associated With manufacturing (if the trials are successful).

An additional point is that European R&D costs are higher than in other world regions due to the fragmented European patent system. The implications of a fragmented patent system in Europe include high uncertainty, quality drop and prohibitive costs, which are at least four times higher than in the US, China and South Korea thus constituting a financial burden on especially small biopharmaceutical enterprises in Europe (van Pottelsberghe 2009).

Market Segment by Manufacturers, this report covers Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck.

The study presents reliable qualitative and quantitative insights into:

Market segments and sub-segments

Market trends and dynamics

Supply and demand chain of the market

Market valuation (revenue and/or volume)

Key trends/opportunities/challenges

Forces defining present and estimated future state of the competitive landscape

Technological developments

Value chain and stakeholder analysis

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Monoclonal Antibodies

Interferon

Colony-Stimulating Factor

Erythropoietin

Insulin

Vaccines

Growth Hormones

Others

Market Segment by Applications, can be divided into

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Inquiry Before Buying at https://www.researchformarkets.com/inquiry/global-biopharmaceuticals-market-113093

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biopharmaceuticals market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.

There are 15 Chapters to deeply display the global Biopharmaceuticals market.

Chapter 1, to describe Biopharmaceuticals Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Biopharmaceuticals, with sales, revenue, and price of Biopharmaceuticals, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Biopharmaceuticals, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Biopharmaceuticals market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Biopharmaceuticals sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Get More Information at https://www.researchformarkets.com/reports/global-biopharmaceuticals-market-113093

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Info:

Name: Research For Markets

Email: [email protected]

Phone: +44 8000-4182-37

#Biopharmaceuticals Biopharmaceuticals Market Global Biopharmaceuticals Market

0 notes

goldsteinresearchinsights · 6 years ago

Text

US Plasma Protein Therapeutics Market is Expected to Grow at a CAGR of 8.45% during the Forecast period (2017-2025)

According to Goldstein Research, Increasing geriatric population, increasing new patient registration for hemophilia treatment, increased penetration of plasma derived products, and rise in the number of clinical indications for immunoglobulin and investments in novel researches are boosting prospects for the market. Moreover, every year, more than 22 million liters of plasma is utilized to manufacture life-saving medicines to treat more than one million people around the world.

US Plasma Protein Therapeutics Market outlook also includes technological innovations, execution strategy and investment strategies adopted by major market players and regional government in order to expand their business across the globe. However, inadequate reimbursement setups and stringent regulations in place that overlook end-to-end management of plasma protein products are restraints to the market’s growth.

Download Exclusive Sample Report @ https://www.goldsteinresearch.com/request-sample/us-plasma-protein-therapeutics-market

Market Segmentation

United States plasma protein therapeutics market report is segmented as follows:

By Product Type

Albumin

Hyperimmunes (IM & IV)

Factor VIII (Plasma Derived)

Factor IX (Plasma Derived)

Polyvalent IVIG/SCIG

By Application

Hemophilia

Primary Immunodeficiency Disorder

Idiopathic Thrombocytopenic Purpura

Secondary Immunodeficiency

Hereditary Angioedema

“US Plasma Protein Therapeutics Market Outlook 2025” contains detailed overview of the US plasma protein therapeutics market. On the basis of our in-depth analysis, market can be segmented in terms of market segmentation by product and by applications.

Further, for the detailed analysis, US Plasma Protein Therapeutics Market Report includes the industry growth drivers, market challenges, market attractiveness, risk analysis and BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis.

US Plasma Protein Therapeutics market report also includes profiling of leading companies such as Baxter, CSL, Grifols, Octapharma, Bayer, Biotest, Kedrion, CBOP, RAAS among other prominent vendors. These company profiles comprise business strategies, geographical revenue share, key information about products, services and industries catered, financial analysis of the company and recent developments.

Overall, US plasma protein therapeutics market report provides the detailed data for present and future trends along with market estimate that will assist industry consultants, technology providers, current market players probing for expansion opportunities and new players searching opportunities to prepare their market centric strategies as per the ongoing and expected trends in the future.

Browse Full Report: https://www.goldsteinresearch.com/report/us-plasma-protein-therapeutics-market

About Goldstein Research

Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.

Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear-cut forecasts.

Our market research report provide in-depth analysis of global and regional variations along with competitors’ overview. Our analysts working on healthcare market reports to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in the vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.

Contact for more Info:

Steve Blade

(Global Sales Head)

USA: + 1-646-568-7747

Canada: 1-437-886-1181

UK: +44-203-318-6627

[email protected]

www.goldsteinresearch.com

#US Plasma Protein Therapeutics Market US Plasma Protein Therapeutics Market Report US Plasma Protein Therapeutics Market Analysis US Plasma

0 notes

marketresearchinsight-blog · 7 years ago

Text

Hemophilia Market Is Expected to Grow at a Estimated CAGR of 5.6% over the forecast period

The Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players’ growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Browse Full Research Report on Hemophilia Market: http://www.grandviewresearch.com/industry-analysis/hemophilia-treatment-industry

Further Key Findings From the Study Suggest:

Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.

On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.

For instance, Grifols has launched the “AlphaNine SD Copay Card” and “ALPHANATE Copay Program” for immediate enrollment in prophylaxis treatment by patients.

On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027.These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.

Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

Grand View Research has segmented the global hemophilia market on the basis of type, treatment, therapy, and region.

Global Hemophilia Market by Type (USD Million), 2013 - 2024

Hemophilia A

Hemophilia B

Hemophilia C

Others

Global Hemophilia Market by Treatment (USD Million), 2013 - 2024

On-demand

Prophylaxis

Global Hemophilia Market Therapy(USD Million), 2013 - 2024

Replacement Therapy

Immune Tolerance Induction Therapy

Gene Therapy

Hemophilia Market By Region (USD Million), 2013 - 2024

North America

US.

Canada

Europe

Germany

Asia-Pacific

Japan

China

Latin America

Brazil

Mexico

Middle East and Africa

South Africa

Saudi Arabia

Browse Press Release of this Report: http://www.grandviewresearch.com/press-release/global-hemophilia-market

About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

0 notes

marketresearchandreports-blog · 7 years ago

Text

Hemophilia Market Is Expected To Grow At A CAGR Of 5.6% From 2016 To 2024: Grand View Research, Inc.

Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/hemophilia-treatment-industry

Further Key Findings From the Study Suggest:

· Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.

· On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.

· For instance, Grifols has launched the “AlphaNine SD Copay Card” and “ALPHANATE Copay Program” for immediate enrollment in prophylaxis treatment by patients.

· On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

· For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027.These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.

· Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global hemophilia market on the basis of type, treatment, therapy, and region.

Global Hemophilia Market by Type (USD Million), 2013 – 2024

· Hemophilia A

· Hemophilia B

· Hemophilia C

· Others

Global Hemophilia Market by Treatment (USD Million), 2013 – 2024

· On-demand

· Prophylaxis

Global Hemophilia Market Therapy(USD Million), 2013 – 2024

· Replacement Therapy

· Immune Tolerance Induction Therapy

· Gene Therapy

Hemophilia Market By Region (USD Million), 2013 – 2024

· North America

o U.S.

o Canada

· Europe

o UK

o Germany

· Asia-Pacific

o Japan

o China

· Latin America

o Brazil

o Mexico

· Middle East and Africa

o South Africa

o Saudi Arabia

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more information: www.grandviewresearch.com

#Hemophilia Market #Hemophilia Market growth #Hemophilia Market size #Hemophilia Market share

0 notes

strategyr-blog · 7 years ago

Text

The Global Apheresis Equipment Market is Projected to Reach US$3.6 Billion by 2024

Rising Demand for Blood Components and Need for Blood Transfusion in Therapy to Drive Growth in the Global Apheresis Equipment Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Apheresis Equipment market. The global Apheresis Equipment market is projected to reach US$3.6 billion by 2024, driven by the increasing prevalence of blood disorders and chronic diseases requiring blood transfusion.

As stated by the new market research report on Apheresis Equipment, the United States represents the largest regional market, worldwide. Growth in the U.S. apheresis equipment market is driven by the rising incidence of hematological disorders and other chronic conditions such as neurological disorders and increasing demand for technologically advanced and automated products. Further, access to advanced healthcare services and favorable reimbursement framework also favors market growth. Asia-Pacific is forecast to grow at the fastest CAGR of 12.1% over the analysis period. The promising outlook for Asia-Pacific is attributed to the rising prevalence of blood-related disorders in emerging economies of China and India. Increase in surgical procedures and trauma and accident cases and improving healthcare infrastructure also bode well for the market.

Major players in the market include Asahi Kasei Medical Co. Ltd., B Braun Melsungen AG, Cerus Corporation, Fresenius Kabi, Haemonetics Corporation, Kaneka Corporation, Kawasumi Laboratories Inc., Mallinckrodt Pharmaceuticals, Medica SpA, NIKKISO Europe GmbH, and Terumo BCT Inc., among others.

The research report titled “Apheresis Equipment: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific (Australia, China and Rest of Asia-Pacific) and Rest of World. The market is analyzed by the product segments - Equipment for Therapeutic Apheresis and Equipment for Donor Apheresis. Global market for Apheresis Equipment is additionally analyzed by Procedure – Photopheresis, Plasmapheresis and Others.

To connect with us, visit our LinkedIn page.

#Apheresis Equipment #Medical Equipment and Supplies

0 notes

strategyr-blog · 8 years ago

Text

The Global Market for Infusion Pumps is Projected to Reach US$13.4 Billion by 2022

Aging Population & Globalization of Unhealthy Lifestyles and the Resulting Rise in Chronic Disease Burden to Drive the Infusion Pumps Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Infusion Pumps market. The global market for Infusion Pumps is projected to reach US$13.4 billion by 2022, driven by factors such as rising disease burden; popularity of infusion therapy for treating diseases unresponsive to oral antibiotics such as cancer, Crohn's disease, hemophilia, immune deficiencies, multiple sclerosis, congestive heart failure, chronic pain, rheumatoid arthritis etc; innovation in smart infusion pumps and migration towards alternate settings for the delivery of infusion therapy.

An infusion pump is a device designed to enable easy administration of nutrients and medications such as insulin, pain relievers, antibiotics, and chemotherapy drugs in accordance with patient requirements. While certain pumps are intended for stationary use, others are suitable for ambulatory applications. The growth in the market is driven by factors such as increasing incidence of chronic diseases, and the ever-present need for safer and advanced infusion technologies. The recent years witnessed some of the major breakthrough developments in bringing interoperability, connectivity and integration into infusion pump systems. Latest advancements and extensive R&D associated with infusion systems and accessories have led to the availability of next-generation smart pumps capable of providing therapeutic treatments for a number of medical conditions. Apart from delivering the dose in a controlled, precise manner, these pumps enable enhanced patient compliance and reduce overall operational costs. Technologies poised to exert strong growth include remotely operated wireless pumps (with dose-calculation and error reduction software (DERS) and drug libraries, Computerized prescriber order entry (CPOE), and Bar-Coded Medication Administration (BCMA) to ensure accurate medication to the concerned patient, among others.

Insulin infusion pumps segment is poised to record the fastest growth largely driven by cutting edge innovations, such as smart insulin pumps incorporated with glucose monitors and meters and easy to apply pump sets. These innovations have in effect simplified and improved the operations, thereby enhancing patient’s care and safety, thus resulting in higher demand. Ambulatory infusion pumps represent another high growth segment. Enteral feeding, also known as artificial nutritional support systems, is perceived as the most preferred treatment option for patients with gastrointestinal tract disorders. Overall adoption of these devices is also supported by technological advancements that have resulted in reliable and safe products capable of avoiding complications including tube dislodgement, misconnections, tube blockage and aspiration. The infusion technology offers an attractive option for parenteral administration of desirable drug formulations for pain management.

As stated by the new market research report on Infusion pumps, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 8.7% over the analysis period, led by factors such as growing population and strong relationship between economic growth, upwardly mobile lifestyles and rise in chronic disease burden; developing healthcare infrastructure and improving accessibility to next-generation healthcare solutions and services; and growing popularity of home or alternate site infusion therapy as a result of high treatment cost in hospital settings and overcrowded and overstretched hospital resources.

Major players covered in the report include Animas Corporation, Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, Halyard Health Inc., Hospira Inc., ICU Medical Inc., Insulet Corporation, Medtronic Plc, Moog Inc., Smiths Medical, Sooil Development Co. Ltd., Tandem Diabetes Care Inc., Teleflex Incorporated, and Terumo Corporation, among others.

The research report titled “Infusion Pumps: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe) Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America) and Rest of World. The report analyses the global and regional markets by the following Product Segments - Ambulatory Infusion Pumps, Enteral Feeding Pumps, Insulin Infusion Pumps, Large Volume Infusion Pumps, PCA Infusion Pumps, and Syringe Infusion Pumps.

0 notes